| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $1,328,553 ) |
| | 2026 | 2026 | TEZCAT BIOSCIENCES, INC. | 470 JAMES STREET | NEW HAVEN | CT | 06513-3175 | SOUTH CENTRAL CT | USA | R41CA306696 | Tumor-targeted delivery of radio/chemotherapy in pancreatic cancer. | 000 | 1 | NIH | 8/18/2026 | $399,855 |
| | 2026 | 2026 | TEZCAT BIOSCIENCES, INC. | 470 JAMES STREET | NEW HAVEN | CT | 06513-3175 | SOUTH CENTRAL CT | USA | R44CA265512 | A novel monobody-drug conjugate to treat mutant KRas pancreatic cancer. | 001 | 3 | NIH | 8/27/2026 | $928,698 |
| | 2026 | 2025 | TEZCAT BIOSCIENCES, INC. | 470 JAMES STREET | NEW HAVEN | CT | 06513-3175 | SOUTH CENTRAL CT | USA | R44CA265512 | A novel monobody-drug conjugate to treat mutant KRas pancreatic cancer. | 000 | 2 | NIH | 11/25/2025 | $0 |
| | 2026 | 2024 | TEZCAT BIOSCIENCES, INC. | 470 JAMES STREET | NEW HAVEN | CT | 06513-3175 | SOUTH CENTRAL CT | USA | R44CA250616 | A novel monobody-drug conjugate to treat mutant Ras multiple myeloma | 000 | 3 | NIH | 8/12/2026 | $0 |
|
| Issue Date FY: 2025 ( Subtotal = $1,318,850 ) |
| | 2025 | 2025 | TEZCAT BIOSCIENCES, INC. | 470 JAMES STREET | NEW HAVEN | CT | 06513-3175 | SOUTH CENTRAL CT | USA | R44CA265512 | A novel monobody-drug conjugate to treat mutant KRas pancreatic cancer. | 000 | 2 | NIH | 8/21/2025 | $1,113,257 |
| | 2025 | 2025 | TEZCAT BIOSCIENCES, INC. | 470 JAMES STREET | NEW HAVEN | CT | 06513-3175 | SOUTH CENTRAL CT | USA | R44CA250616 | A novel monobody-drug conjugate to treat mutant Ras multiple myeloma | 000 | 3 | NIH | 5/13/2025 | $205,593 |
|
| Issue Date FY: 2024 ( Subtotal = $928,011 ) |
| | 2024 | 2024 | TEZCAT BIOSCIENCES, INC. | 470 JAMES STREET | NEW HAVEN | CT | 06513-3175 | SOUTH CENTRAL CT | USA | R44CA250616 | A novel monobody-drug conjugate to treat mutant Ras multiple myeloma | 000 | 3 | NIH | 7/29/2024 | $928,011 |
| | 2024 | 2021 | TEZCAT BIOSCIENCES, INC. | 470 JAMES STREET | NEW HAVEN | CT | 06513-3175 | SOUTH CENTRAL CT | USA | R41CA265512 | A novel monobody-drug conjugate to treat mutant KRas pancreatic cancer. | 000 | 1 | NIH | 2/1/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $1,062,082 ) |
| | 2023 | 2023 | TEZCAT BIOSCIENCES, INC. | 470 JAMES STREET | NEW HAVEN | CT | 06513-3175 | SOUTH CENTRAL CT | USA | R44CA250616 | A novel monobody-drug conjugate to treat mutant Ras multiple myeloma | 000 | 2 | NIH | 7/20/2023 | $1,062,082 |
|
| Issue Date FY: 2022 ( Subtotal = $209,986 ) |
| | 2022 | 2022 | TEZCAT LABORATORIES LLC | 5 W 16TH ST | NEW YORK | NY | 10011-6379 | NEW YORK | USA | R41CA265512 | A novel monobody-drug conjugate to treat mutant KRas pancreatic cancer. | 000 | 1 | NIH | 8/24/2022 | $209,986 |
| | 2022 | 2020 | TEZCAT LABORATORIES LLC | 5 W 16TH ST | NEW YORK | NY | 10011-6379 | NEW YORK | USA | R41CA250616 | A novel monobody-drug conjugate to treat mutant Ras multiple myeloma | 000 | 1 | NIH | 9/15/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $398,715 ) |
| | 2021 | 2021 | TEZCAT LABORATORIES LLC | 10261 TWIN LAKE LOOP | DRIPPING SPRINGS | TX | 78620-2629 | HAYS | USA | R41CA265512 | A novel monobody-drug conjugate to treat mutant KRas pancreatic cancer. | 000 | 1 | NIH | 8/25/2021 | $398,715 |
|
| Issue Date FY: 2020 ( Subtotal = $399,877 ) |
| | 2020 | 2020 | TEZCAT LABORATORIES LLC | 5 W 16TH ST APT 12 | NEW YORK | NY | 10011-6379 | NEW YORK | USA | R41CA250616 | A novel monobody-drug conjugate to treat mutant Ras multiple myeloma | 000 | 1 | NIH | 7/15/2020 | $399,877 |
|
|
